Active Ingredient: The main active ingredient of the medicine is, Almotriptan Malate. This component is the malate salt of almotriptan, a sulfonamide triptan with vasoconstrictor activity. It binds to and activates serotonin 5-HT 1B and 1D receptors in the central nervous system to cause cerebral blood vessel constriction. This may lead to pain relief from vascular headaches. It relieves vascular headaches by preventing the release of vasoactive neuropeptides from perivascular trigeminal axons in the dura mater during a migraine, by reducing extravasation of plasma proteins, and by decreasing the release of other mediators of inflammation from the trigeminal nerve.
Indications: Almotriptan composed medicine Axert is used to treat migraines. This medicine also helps to relieve headache, pain, and other migraine symptoms such as nausea, vomiting, sensitivity to light/sound. Prompt treatment helps you return to your normal routine and may decrease your need for other pain medications. It belongs to a class of drugs known as triptans. It affects a certain natural substance (serotonin) that narrows blood vessels in the brain. It may also relieve pain by affecting certain nerves in the brain. It does not prevent future migraines or lessen how often you get migraine attacks.
Action Mechanism: Triptan medication axert is useful to treat migraine headaches. Migraine headaches are thought to be caused by the dilation of the blood vessels in the head. Almotriptan composed drug works by causing the blood vessels of the head to constrict. It also eliminates or reduces the symptoms of migraine attacks including headache, nausea, vomiting, and sensitivity to light and sound.
Dosages: This medication is available for oral consumption and in dosage as mentioned below:
- 6.25 mg: It is to be taken with or without food as directed by the doctor at the first sign of a migraine
- 12.5 mg: This tablet shall be taken exactly as directed by the doctor
Note: Do not take almotriptan composed medicine to prevent a migraine.
There are no reviews yet.